{Reference Type}: Case Reports
{Title}: Lorlatinib After Alectinib-Induced Pneumonitis: A Case Report.
{Author}: Fletcher JA;Mullally WJ;Ladwa R;O'Byrne KJ;
{Journal}: JTO Clin Res Rep
{Volume}: 5
{Issue}: 2
{Year}: 2024 Feb
暂无{DOI}: 10.1016/j.jtocrr.2023.100591
{Abstract}: ALK gene rearrangements are detected in approximately 3% to 5% of NSCLC. ALK tyrosine kinase inhibitors, such as third-generation lorlatinib, have exhibited remarkable efficacy in ALK-rearranged NSCLC; however, they have been associated with a low incidence of treatment-limiting and potentially fatal drug-induced interstitial lung disease (ILD). There is concern that this may represent a class effect, a theory that is supported by a number of case reports. Because of clinical trial exclusion criteria, there are limited prospective data to guide decision-making after ALK tyrosine kinase inhibitors-induced ILD. A systematic review of the literature was conducted and only identified four reported cases of lorlatinib safety in this context. Here, we report the successful sequencing of lorlatinib in a patient who discontinued alectinib secondary to grade 3 drug-induced ILD.